Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
← catalyst calendarNCT05138133 · readout in 187 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
363actual
Sites
164
Countries
Argentina, Belgium, Brazil +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-15 | actual | When the study began enrolling |
| Primary completion | 2027-02-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-04 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lupus Nephritis
Interventions
- Drug: Anifrolumab — also filed as Medi-546
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFDifference in proportion of participants with CRR (Complete Renal Response) in anifrolumab group compared with placebo group
measured Week 52
Publications
- PMID 42175562 — linked by the registry
- PMID 37528520 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed